Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial-Reference-Cited by-同舟云学术

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

Published:2014-02 Issue:2 Volume:25 Page:429-434
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sternberg C.N.,de Bono J.S.,Chi K.N.,Fizazi K.,Mulders P.,Cerbone L.,Hirmand M.,Forer D.,Scher H.I.

Funder

Medivation, Inc. and Astellas

AFFIRM

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/2/429/16699861/mdt571.pdf

Reference18 articles.

1. Management of metastatic prostate cancer: the crucial role of geriatric assessment;Droz;BJU Int,2008

2. Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based study;de Camargo Cancela;Br J Cancer,2013

3. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality;Scosyrev;Cancer,2012

4. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer;Italiano;Eur Urol,2009

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PROTACing the androgen receptor and other emerging therapeutics in prostate cancer;Expert Review of Anticancer Therapy;2024-07-22

2. Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy;Drug Safety;2024-04-12

3. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis;European Urology Oncology;2023-12

4. Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort;Journal of Geriatric Oncology;2023-11

5. Adverse Events of Abiraterone Acetate vs Enzalutamide;Urology Practice;2023-07